Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Pulls Back From First-Line CLL As Revlimid ORIGIN Trial Terminates

This article was originally published in The Pink Sheet Daily

Executive Summary

Imbalance of deaths for Revlimid in the ORIGIN treatment-naïve CLL study could be due to the advanced age of participants or their many comorbidities. Future of drug as monotherapy in treatment-naïve patients is now unlikely, but studies in later lines of treatment go on.


Related Content

Celgene Secures Revlimid Frontline Myeloma Approval
Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts